Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with Luspatercept

Ralph V. Boccia(Center for Cancer and Blood Disorders), Aylin Yücel(Bristol-Myers Squibb (United States)), Ali McBride(University of Arizona), Dimana Miteva(Bristol-Myers Squibb (Switzerland)), Tao Gu(Yunnan Center for Disease Control And Prevention), Min Che(Northeast Normal University), Hong Xiao(Shanxi Medical University), Mrudula B. Glassberg(Bristol-Myers Squibb (United States))
Blood
November 2, 2023
10.1182/blood-2023-173360
Cited by 1

Related Papers

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425
Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
|The Lancet Oncology|2013|387
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|386
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
|Journal of Clinical Oncology|2012|373